Shopping Cart
Remove All
Your shopping cart is currently empty
Blonanserin
Copy Product Info
🥰Excellent
Catalog No. T1180Cas No. 132810-10-7
Alias AD-5423
Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.
Blonanserin
Copy Product Info🥰Excellent
Purity: 99.99%
Catalog No. T1180Alias AD-5423Cas No. 132810-10-7
Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $44 | In Stock | In Stock | |
| 50 mg | $64 | In Stock | In Stock | |
| 100 mg | $89 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.99%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Blonanserin AI Summary
Blonanserin exhibits high binding affinity in in vitro assays against human dopamine receptor D2L (Ki = 0.14 nM) and human 5-hydroxytryptamine 2A receptor (Ki = 0.81 nM). It also demonstrates bioactivity as an inhibitor of entry for various viruses, including Lassa Virus, Marburg Virus, and Ebola Virus, with potency ranging from 12589.3 nM to 1.413 µM. In the context of SARS-CoV-2, Blonanserin shows minimal antiviral activity in certain assays, with low to moderate inhibition rates observed in different cell lines (e.g., 3.22% inhibition in Caco-2 cells at 10 µM after 48 hours, 28.63% and 5.707% inhibition of 3CL-Pro protease at 20 µM, and approximately 0.11% inhibition in VERO-6 cells at 10 µM). Additionally, it exhibits some inhibition of human HDAC6 activity (17.51% with a commercial peptide substrate), though this activity is inconsistent across different substrates. These findings suggest that while Blonanserin has potent receptor binding and some antiviral properties, its efficacy can vary depending on the specific viral target and experimental conditions..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. |
| Targets&IC50 | 5-HT2:3.98 nM(Ki), D4 Receptor:150 nM (Ki), D3 receptor:0.494 nM (Ki), 5-HT2C receptor:26.4 nM (Ki), α2-adrenoceptor:530 nM (Ki, rat), 5-HT2A receptor:0.812 nM (Ki), D2 receptor:14.8 nM(Ki), α1-adrenoceptor:26.7 nM (Ki, rat), 5-HT6 receptor:11.7 nM (Ki), D1 receptor:1070 nM (Ki) |
| In vitro | In tests of atypical antipsychotics (risperidone, olanzapine, and aripiprazole), Blonanserin showed the most potent binding affinity for human D3 receptors.Blonanserin transiently increased neuronal firing in the nucleus of the pallidum and ventral tegmental area, but not in the nucleus medius dorsalis or the medial dorsal nucleus of the thalamus, whereas risperidone increased firing in the nucleus ventral tegmental area and in the nucleus medius dorsalis but not in the nucleus dorsalis. in the medial dorsal nucleus of the rat thalamus. Blonanserin consistently increased additional extracellular levels of norepinephrine and dopamine but not serotonin, GABA, or glutamate, whereas risperidone consistently increased levels of norepinephrine, dopamine, and serotonin but not GABA or glutamate.Blonanserin increased the efflux of cortical DA and its metabolites, homovanillic acid and 3,4-dihydroxy Phenylacetic acid. |
| In vivo | In tests of atypical antipsychotics (risperidone, olanzapine, and aripiprazole), Blonanserin showed the most potent binding affinity for human D3 receptors.Blonanserin transiently increased neuronal firing in the nucleus of the pallidum and ventral tegmental area, but not in the nucleus medius dorsalis or the medial dorsal nucleus of the thalamus, whereas risperidone increased firing in the nucleus ventral tegmental area and in the nucleus medius dorsalis but not in the nucleus dorsalis. in the medial dorsal nucleus of the rat thalamus. Blonanserin consistently increased additional extracellular levels of norepinephrine and dopamine but not serotonin, GABA, or glutamate, whereas risperidone consistently increased levels of norepinephrine, dopamine, and serotonin but not GABA or glutamate.Blonanserin increased the efflux of cortical DA and its metabolites, homovanillic acid and 3,4-dihydroxy Phenylacetic acid. |
| Synonyms | AD-5423 |
| Molecular Weight | 367.50 |
| Formula | C23H30FN3 |
| Cas No. | 132810-10-7 |
| Smiles | FC1=CC=C(C2=C3C(=NC(=C2)N4CCN(CC)CC4)CCCCCC3)C=C1 |
| Relative Density. | 1.095 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 14.29 mg/mL (38.88 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.00 mg/mL (2.72 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
social deficitSigmareceptorSigma ReceptorSerotonin ReceptorschizophreniaInhibitorinhibithypotensionextrapyramidal symptomexcessive sedationDopamineReceptorDopamine ReceptorDopamineD2BlonanserinBeta ReceptorantipsychoticAdrenergicReceptorAdrenergic ReceptorAD5423AD 54235-hydroxytryptamine Receptor5HTReceptor5-HT25-HT Receptor5HT Receptor
Preview
Related Tags: buy Blonanserin | purchase Blonanserin | Blonanserin cost | order Blonanserin | Blonanserin chemical structure | Blonanserin in vivo | Blonanserin in vitro | Blonanserin formula | Blonanserin molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.